Interactions between gamma-aminobutyric capped silver nanoparticles and large unilamellar vesicles (LUVs) and their antimicrobial activities

Multidrug-resistant bacteria (MDR) and bacterial virulence pose significant challenges to global health. Nanotechnology offers exciting possibilities for developing innovative strategies to combat these issues. This study investigates the synergistic effects of silver nanoparticles (AgNPs) and gamma-aminobutyric acid (GABA) to address antibiotic resistance and bacterial virulence. We report the synthesis and characterization of GABA-coated AgNPs (GABAAgNPs) using UV–VIS and infrared spectroscopies, zeta potential, X-ray diffraction, and transmission electron microscopy. The interaction between GABAAgNPs and model membranes (large unilamellar vesicles, LUVs) was assessed, revealing the formation of liposomal-bound GABAAgNPs (LPGABAAgNPs). Antimicrobial activity against E. coli ATCC 25922 demonstrated that LPGABAAgNPs exhibit enhanced antibacterial efficacy compared to free GABAAgNPs. These findings suggest that liposomal delivery of GABAAgNPs is a promising approach for optimizing their antibacterial properties. Moreover, incorporating GABA into the nanoparticle system offers the potential to modulate bacterial virulence, providing a multifaceted strategy to combat infection.

Synthesis and biological activities of a nitro-shiff base compound as a potential anti-inflammatory agent.

In order to discover a new compound having anti-inflammatory activity, a nitro-Schiff base was evaluated. The compound was synthesized and characterized by 1H NMR and 13C NMR. The cytotoxic activity was evaluated in vitro by hemolysis and MTT cell viability assay. To evaluate genotoxicity, the micronucleus assay was performed in vivo. The anti-inflammatory effects of the compound were examined using in vivo models of inflammation such as neutrophil migration assay, paw edema, and exudation assay. The production of NO was also estimated in vivo and in vitro. The data showed that the compound did not induce hemolysis at all the tested concentrations. Similarly, the compound did not induce cytotoxicity and genotoxicity to the cells. The neutrophil migration assay showed that the compound reduced the number of neutrophils recruited to the peritoneal cavity by approximately 60% at all the tested concentrations. In the exudation assay, the compound showed a reduction in extravasation by 24%. The paw edema model demonstrated a significant reduction in the paw volume at all the evaluated time points. The production of NO was decreased both in vitro and in vivo. These results suggest that the nitro-Schiff base compound efficiently inhibited inflammation and might be a good candidate for the treatment of inflammatory-associated conditions.